Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | SVP/Chief Comm Off, Alks Inc | March 01, 2018 | March 05, 2018 |
| Indivior Pharmaceuticals, Inc.INDV · Entity 4040 | Director | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date March 01, 2018 · Filed March 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 51,065 |
Ending reported balance
After 2018-03-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-03-01 · Exercise / conversion · Acquired 5,250 · Balance 51,837 Row 2 · 2018-03-01 · Tax withholding · Disposed 2,334 · Balance 49,503 Row 3 · 2018-03-03 · Exercise / conversion · Acquired 2,813 · Balance 52,316 Row 4 · 2018-03-03 · Tax withholding · Disposed 1,251 · Balance 51,065 |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,500 |
Reported balance
After 2018-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-01 · Exercise / conversion · Disposed 5,250 · Balance 10,500 F1: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-03-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-03-03 · Exercise / conversion · Disposed 2,813 · Balance 0 F2: This RSU award is fully vested in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017.
F2: This RSU award is fully vested in accordance with its terms.
Indivior Pharmaceuticals, Inc.
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,087 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 6,518 · Balance 27,087 F1: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 12,631 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.87 · Expires 2026-09-12 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.16 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.14 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.74 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.22 · Expires 2031-06-23 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 14, 2026 20:07 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantCommon Stock | 6,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001487937-26-000009 · wk-form4_1778789230.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,087 F1 · shares: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:08 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantCommon Stock | 3,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001487937-26-000006 · wk-form4_1769634491.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,569 F1 · shares: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 18:48 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | PurchaseOrdinary Shares | 775 | $35.39 | $27,429.27 |
DisclosureSEC source: 0001487937-26-000004 · wk-form4_1767811690.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,847 F1 · kind: Securities acquired pursuant to the director's participation in a Non-Executive Director Purchase Plan to receive a portion of the fees received for service as a director in stock in lieu of cash. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 15:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 7,000 | Not disclosed Strike: $9.22 | Not disclosed |
DisclosureSEC source: 0001209191-21-065722 · doc4.xml · derivative · entry 7 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2031-06-23 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 15:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 7,000 | Not disclosed Strike: $11.88 | Not disclosed |
DisclosureSEC source: 0001209191-21-065722 · doc4.xml · derivative · entry 6 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2030-06-09 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 15:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $11.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-065722 · doc4.xml · derivative · entry 5 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2029-06-18 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 15:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $28.14 | Not disclosed |
DisclosureSEC source: 0001209191-21-065722 · doc4.xml · derivative · entry 4 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2028-06-19 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 15:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $20.16 | Not disclosed |
DisclosureSEC source: 0001209191-21-065722 · doc4.xml · derivative · entry 3 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 15:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $15.87 | Not disclosed |
DisclosureSEC source: 0001209191-21-065722 · doc4.xml · derivative · entry 2 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-09-12 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 15:20 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerCommon Stock | 12,631 | $8.50 | $107,363.50 |
DisclosureSEC source: 0001209191-21-065722 · doc4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2 · shares: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:30 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 7,000 | $0.00 Strike: $9.22 | $0.00 |
DisclosureSEC source: 0001209191-21-043552 · doc4.xml · derivative · entry 2 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-06-23 F3 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:30 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043552 · doc4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,631 F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. F2 · balance_after: 1,580 shares previously held by The Mark P. Stejbach Revocable Trust UA 07-08-2016 are now held by the Reporting Person directly. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:25 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 7,000 | $0.00 Strike: $11.88 | $0.00 |
DisclosureSEC source: 0001209191-20-036282 · doc4.xml · derivative · entry 3 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:25 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036282 · doc4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,551 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| May 26, 2020 Filed May 27, 2020 20:14 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 2,051 | $9.75 | $19,997.25 |
DisclosureSEC source: 0001209191-20-032291 · doc4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,051 F1 · kind: The shares were purchased in connection with the Issuer's public offering. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:15 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0001209191-19-038463 · doc4.xml · derivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-06-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 20:23 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $28.14 | $0.00 |
DisclosureSEC source: 0001209191-18-038945 · doc4.xml · derivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-06-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| March 03, 2018 Filed Mar 5, 2018 23:33 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 2,813 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010224 · form4.xml · derivative · entry 6 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This RSU award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This RSU award is fully vested in accordance with its terms. Read SEC document |
| March 03, 2018 Filed Mar 5, 2018 23:33 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,251 | $60.05 | $75,122.55 |
DisclosureSEC source: 0001127602-18-010224 · form4.xml · nonDerivative · entry 4 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,065 Read SEC document |
| March 03, 2018 Filed Mar 5, 2018 23:33 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010224 · form4.xml · nonDerivative · entry 3 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:33 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 5,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010224 · form4.xml · derivative · entry 5 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 5,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:33 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 2,334 | $57.41 | $133,994.94 |
DisclosureSEC source: 0001127602-18-010224 · form4.xml · nonDerivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,503 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:33 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010224 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:46 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 2,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-009216 · form4.xml · derivative · entry 4 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625 Underlying: Ordinary Shares · 2,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/26/2016. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/26/2016. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:46 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,167 | $58.12 | $67,826.04 |
DisclosureSEC source: 0001127602-18-009216 · form4.xml · nonDerivative · entry 3 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,587 Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:46 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-009216 · form4.xml · nonDerivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2018 Filed Feb 28, 2018 23:46 UTC | Alkermes plc. ALKS · Entity 2392 | GiftOrdinary Shares | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-009216 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,129 Read SEC document |
| February 17, 2018 Filed Feb 21, 2018 23:10 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007606 · form4.xml · derivative · entry 8 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. Read SEC document |
| February 17, 2018 Filed Feb 21, 2018 23:10 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 884 | $67.26 | $59,457.84 |
DisclosureSEC source: 0001127602-18-007606 · form4.xml · nonDerivative · entry 4 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,129 Read SEC document |
| February 17, 2018 Filed Feb 21, 2018 23:10 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007606 · form4.xml · nonDerivative · entry 3 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:10 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 13,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007606 · form4.xml · derivative · entry 7 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Ordinary Shares · 13,500 shares Expires not disclosed F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:10 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 54,500 | $0.00 Strike: $67.26 | $0.00 |
DisclosureSEC source: 0001127602-18-007606 · form4.xml · derivative · entry 6 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,500 Underlying: Ordinary Shares · 54,500 shares Expires 2028-02-16 F5 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/16/2019. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:10 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,880 | $0.00 Strike: $17.30 | $0.00 |
DisclosureSEC source: 0001127602-18-007606 · form4.xml · derivative · entry 5 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,780 Underlying: Ordinary Shares · 10,880 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/5/17. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:10 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 10,880 | $70.50 | $767,092.22 |
DisclosureSEC source: 0001127602-18-007606 · form4.xml · nonDerivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,013 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/5/17. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.14 to $70.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:10 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 10,880 | $17.30 | $188,224.00 |
DisclosureSEC source: 0001127602-18-007606 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/5/17. Read SEC document |
| June 22, 2017 Filed Jul 27, 2017 13:44 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001209191-17-046394 · doc4.xml · derivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 20:24 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 1,580 | $17.02 | $26,888.12 |
DisclosureSEC source: 0001209191-17-041093 · doc4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Mark P. Stejbach Revocable Trust UA 07-08-2016 Disclosed balance after: 1,580 Read SEC document |
| June 08, 2017 Filed Jun 8, 2017 21:41 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.30 | $0.00 |
DisclosureSEC source: 0001127602-17-020963 · form4.xml · derivative · entry 3 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,660 Underlying: Ordinary Shares · 10,000 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/5/17. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| June 08, 2017 Filed Jun 8, 2017 21:41 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 10,000 | $60.34 | $603,352.00 |
DisclosureSEC source: 0001127602-17-020963 · form4.xml · nonDerivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,013 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/5/17. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 08, 2017 Filed Jun 8, 2017 21:41 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 10,000 | $17.30 | $173,000.00 |
DisclosureSEC source: 0001127602-17-020963 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/5/17. Read SEC document |
| May 28, 2017 Filed May 30, 2017 21:51 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-019723 · form4.xml · derivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This RSU award is fully vested in accordance with its terms. F1 · derivative.expiration_date: This RSU award is fully vested in accordance with its terms. Read SEC document |
| May 28, 2017 Filed May 30, 2017 21:51 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-019723 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:50 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 2,812 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010471 · form4.xml · derivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,813 Underlying: Ordinary Shares · 2,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/3/2015. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/3/2015. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:50 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010471 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:19 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 5,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009864 · form4.xml · derivative · entry 3 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Ordinary Shares · 5,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:19 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 2,437 | $59.71 | $145,513.27 |
DisclosureSEC source: 0001127602-17-009864 · form4.xml · nonDerivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,701 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:19 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009864 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2017 Filed Feb 27, 2017 22:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 2,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-008691 · form4.xml · derivative · entry 3 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Ordinary Shares · 2,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/26/2016. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/26/2016. Read SEC document |
| February 26, 2017 Filed Feb 27, 2017 22:52 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 852 | $52.98 | $45,138.96 |
DisclosureSEC source: 0001127602-17-008691 · form4.xml · nonDerivative · entry 2 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,888 Read SEC document |
| February 26, 2017 Filed Feb 27, 2017 22:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-008691 · form4.xml · nonDerivative · entry 1 Stejbach Mark · CIK 0001487937 · SVP/Chief Comm Off, Alks Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.